{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:32:21Z","timestamp":1776166341695,"version":"3.50.1"},"posted":{"date-parts":[[2026,4,14]]},"group-title":"In Review","reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,25]]},"abstract":"<title>Abstract<\/title>\n                <p>Multiple myeloma (MM) is a plasma cell malignancy marked by profound immune dysfunction and substantial infection-related mortality. MM is preceded by the asymptomatic precursor states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), yet whether these patients can mount effective immune responses remains unknown. In this prospective observational study of 731 individuals recruited nationwide through Dana-Farber Cancer Institute, we used SARS-CoV-2 vaccination as a standardized immunological challenge alongside childhood vaccine serology. We show that precursor myeloma is associated with broad dysfunction across innate and adaptive immunity, including accelerated antibody waning, erosion of childhood vaccine titers, impaired antigen-specific T cell expansion, and blunted innate activation. Mechanistically, we link these defects to tumor burden-dependent APRIL depletion and downregulation of APRIL-responsive pathways in normal plasma cells, validated in an independent cohort. These findings have direct implications for cancer vaccine development, immunotherapy, and infection management in early-stage hematologic malignancies.<\/p>","DOI":"10.21203\/rs.3.rs-9226435\/v1","type":"posted-content","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:17:11Z","timestamp":1776161831000},"source":"Crossref","is-referenced-by-count":0,"title":["Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene","family":"Ghobrial","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noe","family":"Perron","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Aranha","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT & Harvard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena Pantano","family":"Rubino","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yue","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Lightbody","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute of MIT & Harvard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riddhiman","family":"Saha","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahshid","family":"Rahmat","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3502","authenticated-orcid":false,"given":"Michael","family":"Timonian","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute of MIT & Harvard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-015X","authenticated-orcid":false,"given":"Daniel","family":"Heilpern-Mallory","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Agius","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveliy","family":"Belkin","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-0071","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Nowak","sequence":"additional","affiliation":[{"name":"Institute of Structural Biology, University Hospital Bonn, University of Bonn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Foundation (MMRF)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn","family":"Cho","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mt. Sinai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5084-9604","authenticated-orcid":false,"given":"George","family":"Mulligan","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-6306","authenticated-orcid":false,"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute\/Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Marinac","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"Broad Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-7212","authenticated-orcid":false,"given":"Yoshinobu","family":"Konishi","sequence":"additional","affiliation":[{"name":"Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass E","year":"2021","unstructured":"Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215\u2013229","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin U","year":"2017","unstructured":"Sahin U et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222\u2013226","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott PA","year":"2017","unstructured":"Ott PA et al (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217\u2013221","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber JS","year":"2024","unstructured":"Weber JS et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas LA","year":"2023","unstructured":"Rojas LA et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144\u2013150","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez J","year":"2025","unstructured":"Lopez J et al (2025) Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med 31:152\u2013164","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari A","year":"2020","unstructured":"Chari A et al (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood 136:3033\u20133040","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury H","year":"2022","unstructured":"El-Khoury H (2022) Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol 9:e340\u2013e349","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of Monoclonal Gammopathy of Undetermined Significance","volume":"354","author":"Kyle RA","year":"2006","unstructured":"Kyle RA et al (2006) Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 354:1362\u20131369","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson S","year":"2021","unstructured":"R\u00f6gnvaldsson S et al (2021) Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J 11:94","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij O","year":"2020","unstructured":"Zavidij O et al (2020) Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1:493\u2013506","journal-title":"Nat Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis R","year":"2022","unstructured":"Sklavenitis-Pistofidis R et al (2022) Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40:1358\u20131373e8","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01006-0","article-title":"SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors","author":"Lightbody ED","year":"2025","unstructured":"Lightbody ED (2025) SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-025-01006-0","journal-title":"Nat Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood.V116.21.4053.4053","article-title":"Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study","volume":"116","author":"Kristinsson SY","year":"2010","unstructured":"Kristinsson SY et al (2010) Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. Blood 116:4053","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas dos Santos DM","year":"2024","unstructured":"Cordas dos Santos DM, Toenges R, Bertamini L, Alberge J-B, Ghobrial IM (2024) New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer 24:867\u2013886","journal-title":"Nat Rev Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2021.12.003","article-title":"Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia","volume":"40","author":"Konishi Y","year":"2022","unstructured":"Konishi Y et al (2022) Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia. Cancer Cell 40:6\u20138","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41423-023-01095-w","article-title":"B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity","volume":"21","author":"Lapuente D","year":"2024","unstructured":"Lapuente D, Winkler TH, Tenbusch M (2024) B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol 21:144\u2013158","journal-title":"Cell Mol Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines10010064","article-title":"Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection","volume":"10","author":"Israel A","year":"2022","unstructured":"Israel A (2022) Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines 10:64","journal-title":"Vaccines"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad EH","year":"2020","unstructured":"Rustad EH (2020) Timing the initiation of multiple myeloma. Nat Commun 11:1917","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02292-1","article-title":"Temporal genomic dynamics shape clinical trajectory in multiple myeloma","author":"Maura F","year":"2025","unstructured":"Maura F (2025) Temporal genomic dynamics shape clinical trajectory in multiple myeloma. Nat Genet. https:\/\/doi.org\/10.1038\/s41588-025-02292-1","journal-title":"Nat Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge JB","year":"2025","unstructured":"Alberge JB (2025) Genomic landscape of multiple myeloma and its precursor conditions. Nat Genet 57:1493\u20131503","journal-title":"Nat Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.025","author":"Yeh T-W","year":"2020","unstructured":"Yeh T-W (2020) APRIL-dependent lifelong plasmacyte maintenance and immunoglobulin production in humans. J. Allergy Clin. Immunol. 146 1109-1120e1104 https:\/\/doi.org\/10.1016\/j.jaci.2020.03.025 doi:10.1016\/j.jaci.2020.03.025"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00721","article-title":"The Maintenance of Memory Plasma Cells","volume":"10","author":"Khodadadi L","year":"2019","unstructured":"Khodadadi L, Cheng Q, Radbruch A, Hiepe F (2019) The Maintenance of Memory Plasma Cells. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.00721","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"102442","DOI":"10.1016\/j.coi.2024.102442","article-title":"New insights into the mechanisms regulating plasma cell survival and longevity","volume":"88","author":"Khamyath M","year":"2024","unstructured":"Khamyath M, Melhem H, Balabanian K, Espeli M (2024) New insights into the mechanisms regulating plasma cell survival and longevity. Curr Opin Immunol 88:102442","journal-title":"Curr Opin Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai Y-T","year":"2016","unstructured":"Tai Y-T et al (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127:3225\u20133236","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux J","year":"2004","unstructured":"Moreaux J (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148\u20133157","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells","volume":"199","author":"O\u2019Connor BP","year":"2004","unstructured":"O\u2019Connor BP et al (2004) BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells. J Exp Med 199:91\u201398","journal-title":"J Exp Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak AJ","year":"2004","unstructured":"Novak AJ et al (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689\u2013694","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen C","year":"2006","unstructured":"Bossen C, Schneider P, BAFF (2006) APRIL and their receptors: structure, function and signaling. Semin Immunol 18:263\u2013275","journal-title":"Semin Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai Y-T","year":"2015","unstructured":"Tai Y-T, Anderson KC (2015) Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7:1187\u20131199","journal-title":"Immunotherapy"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA","volume":"32","author":"Coquery CM","year":"2012","unstructured":"Coquery CM, Erickson LD (2012) Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA. Crit Rev Immunol 32:287\u2013305","journal-title":"Crit Rev Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Nobari ST","year":"2022","unstructured":"Nobari ST, Nojadeh JN, Talebi M (2022) B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med 20:82","journal-title":"J Transl Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent Engagement of the Classical and Alternative NF-\u03baB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma","volume":"12","author":"Annunziata CM","year":"2007","unstructured":"Annunziata CM et al (2007) Frequent Engagement of the Classical and Alternative NF-\u03baB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma. Cancer Cell 12:115\u2013130","journal-title":"Cancer Cell"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay F","year":"2009","unstructured":"Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:491\u2013502","journal-title":"Nat Rev Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.2100623","article-title":"APRIL Drives a Coordinated but Diverse Response as a Foundation for Plasma Cell Longevity","volume":"209","author":"Stephenson S","year":"2022","unstructured":"Stephenson S, Care MA, Doody GM, Tooze RM (2022) APRIL Drives a Coordinated but Diverse Response as a Foundation for Plasma Cell Longevity. J Immunol 209:926\u2013937","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky R","year":"2022","unstructured":"Boiarsky R et al (2022) Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun 13:7040","journal-title":"Nat Commun"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109504","article-title":"Systemic IL-15, IFN-\u03b3, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients","volume":"36","author":"Bergamaschi C","year":"2021","unstructured":"Bergamaschi C et al (2021) Systemic IL-15, IFN-\u03b3, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep 36","journal-title":"Cell Rep"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui A","year":"2024","unstructured":"Cui A et al (2024) Dictionary of immune responses to cytokines at single-cell resolution. Nature 625:377\u2013384","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v30.i6.10","author":"Matsumiya T","year":"2010","unstructured":"Matsumiya T, Stafforini DM (2010) Function and Regulation of Retinoic Acid-Inducible Gene-I. 30 489\u2013513 https:\/\/doi.org\/10.1615\/CritRevImmunol.v30.i6.10 doi:10.1615\/CritRevImmunol.v30.i6.10"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","article-title":"Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors","volume":"18","author":"Onomoto K","year":"2021","unstructured":"Onomoto K, Onoguchi K, Yoneyama M (2021) Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol Immunol 18:539\u2013555","journal-title":"Cell Mol Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"46655","DOI":"10.1074\/jbc.M108636200","article-title":"Targeting of NEDD8 and Its Conjugates for Proteasomal Degradation by NUB1 *","volume":"276","author":"Kamitani T","year":"2001","unstructured":"Kamitani T, Kito K, Fukuda-Kamitani T, Yeh ETH (2001) Targeting of NEDD8 and Its Conjugates for Proteasomal Degradation by NUB1 *. J Biol Chem 276:46655\u201346660","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"35756","DOI":"10.1074\/jbc.M112.397703","article-title":"Inhibition of neddylation represses lipopolysaccharide-induced proinflammatory cytokine production in macrophage cells","volume":"287","author":"Chang F-M","year":"2012","unstructured":"Chang F-M (2012) Inhibition of neddylation represses lipopolysaccharide-induced proinflammatory cytokine production in macrophage cells. J Biol Chem 287:35756\u201335767","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.matbio.2007.07.001","article-title":"Control of matrix metalloproteinase catalytic activity","volume":"26","author":"Ra HJ","year":"2007","unstructured":"Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587\u2013596","journal-title":"Matrix Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark C","year":"2015","unstructured":"Blimark C et al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100:107\u2013113","journal-title":"Haematologica"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin U","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6 (2018) Personalized vaccines for cancer immunotherapy. Science 359:1355\u20131360","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"104363","DOI":"10.1016\/j.ebiom.2022.104363","article-title":"Immunopathophysiology of human sepsis","volume":"86","author":"Wiersinga WJ","year":"2022","unstructured":"Wiersinga WJ, van der Poll T (2022) Immunopathophysiology of human sepsis. eBioMedicine 86:104363","journal-title":"eBioMedicine"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1152\/physrev.00031.2021","article-title":"Trained immunity: adaptation within innate immune mechanisms","volume":"103","author":"Dom\u00ednguez-Andr\u00e9s J","year":"2023","unstructured":"Dom\u00ednguez-Andr\u00e9s J et al (2023) Trained immunity: adaptation within innate immune mechanisms. Physiol Rev 103:313\u2013346","journal-title":"Physiol Rev"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales L","year":"2015","unstructured":"Corrales L et al (2015) Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep 11:1018\u20131030","journal-title":"Cell Rep"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of Therapeutic STING Activation Determines CD8\u2009+\u2009T Cell-Mediated Anti-tumor Immunity","volume":"25","author":"Sivick KE","year":"2018","unstructured":"Sivick KE et al (2018) Magnitude of Therapeutic STING Activation Determines CD8\u2009+\u2009T Cell-Mediated Anti-tumor Immunity. Cell Rep 25:3074\u20133085e5","journal-title":"Cell Rep"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini Y","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol 57:289\u2013300","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem O","year":"2025","unstructured":"Nadeem O (2025) Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat Commun 16:358","journal-title":"Nat Commun"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng GX","year":"2017","unstructured":"Zheng GX (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049","journal-title":"Nat Commun"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"D419","DOI":"10.1093\/nar\/gkx760","article-title":"VDJdb: a curated database of T-cell receptor sequences with known antigen specificity","volume":"46","author":"Shugay M","year":"2018","unstructured":"Shugay M (2018) VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res 46:D419\u2013D427","journal-title":"Nucleic Acids Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","article-title":"McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences","volume":"33","author":"Tickotsky N","year":"2017","unstructured":"Tickotsky N, Sagiv T, Prilusky J, Shifrut E, Friedman N (2017) McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics 33:2924\u20132929","journal-title":"Bioinformatics"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1488851","DOI":"10.3389\/fimmu.2025.1488851","article-title":"A large-scale database of T-cell receptor beta sequences and binding associations from natural and synthetic exposure to SARS-CoV-2","volume":"16","author":"Nolan S","year":"2025","unstructured":"Nolan S (2025) A large-scale database of T-cell receptor beta sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. Front Immunol 16:1488851","journal-title":"Front Immunol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/bioinformatics\/btab446","article-title":"ClusTCR: a python interface for rapid clustering of large sets of CDR3 sequences with unknown antigen specificity","volume":"37","author":"Valkiers S","year":"2021","unstructured":"Valkiers S, Van Houcke M, Laukens K, Meysman P (2021) ClusTCR: a python interface for rapid clustering of large sets of CDR3 sequences with unknown antigen specificity. Bioinformatics 37:4865\u20134867","journal-title":"Bioinformatics"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9226435\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9226435\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:17:21Z","timestamp":1776161841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9226435\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":56,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9226435\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,4,14]]},"subtype":"preprint"}}